Current Report Filing (8-k)
October 26 2016 - 8:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 26, 2016
Minerva Neurosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36517
|
|
26-0784194
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
1601 Trapelo Road
Suite 284
Waltham,
MA
|
|
02451
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrant’s telephone number, including area code): (617)
600-7373
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
On October 26, 2016, Minerva Neurosciences, Inc. (the “Company”) issued a
press release announcing data from the 24-week open-label extension of its 12-week, randomized, double-blind, placebo-controlled Phase IIb clinical trial of
MIN-101
as monotherapy in patients with negative
symptoms of schizophrenia. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the Company’s presentation that includes supporting data for the press release is filed as Exhibit
99.2 to this Current Report on Form 8-K.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release of the Company dated October 26, 2016
|
|
|
|
|
99.2
|
|
Presentation of the Company dated October 26, 2016
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
MINERVA NEUROSCIENCES, INC.
|
|
|
|
|
By:
|
|
/s/ Mark S. Levine
|
|
Name:
|
|
Mark S. Levine
|
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
Date: October 26, 2016
INDEX OF EXHIBITS
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release of the Company dated October 26, 2016
|
|
|
|
|
99.2
|
|
Presentation of the Company dated October 26, 2016
|
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024
